1.
The national contact points designated in accordance with Article 83 of Regulation (EU) No 536/2014 shall communicate, within theClinical Trials Coordination and Advisory Group, any concerns related to the functioning of the coordinated safety assessments that they receive from their designating Member States, the safety assessing Member States, or the public.
2.
The Clinical Trials Coordination and Advisory Group shall investigate and address concerns related to the functioning of the coordinated safety assessment in due time.